Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pivekimab Sunirine Clear all
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Palo Alto, California • Valhalla, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT06034470
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography, Fludarabine, Granulocyte Colony-Stimulating Factor, Idarubicin, Multigated Acquisition Scan, Pivekimab Sunirine
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 11, 2026, 2:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 2:15 PM EDT